Anika Therapeutics (ANIK) Misses Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.06 +0.91%
EPS Growth %: -125.0%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: -125.0%
Financial Fact:
Selling, general & administrative: 4.28M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.46, $0.01 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $27.2 million versus the consensus estimate of $28.92 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- Kustom Entertainment agrees to buy Tickets For Less operator TFL
- Humana reaffirms 2026 earnings guidance ahead of investor meetings
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
